Immune Pharmaceuticals, Inc. (NASDAQ: IMNP) ("Immune or the "Company") announced today that its Chief Executive Officer, Dr. Daniel Teper, has established a stock trading plan with respect to the purchases of up to an aggregate of $250,000 of shares of Immune common stock in accordance with Rule 10b5-1 under the Exchange Act and other applicable federal securities laws and regulations adopted by the Securities and Exchange Commission. The transactions under this plan will be disclosed publicly through Form 4 filings with the Securities and Exchange Commission.
Dr. Teper had recently purchased 7,569 shares of Immune common stock at $1.29 per share on September 1, 2015. More recently, two members of the Board of Directors of Immune purchased 50,000 shares of Immune common stock at $1.47 per share and 50,000 shares of Immune common stock at $1.48 per share respectively. These purchases by Dr. Teper and the members of the Board of Directors, respectively, are reflected in Forms 4 Statement of Change in Beneficial Ownership of Securities filed with the Securities and Exchange Commission.
Danish studies find increased risk of optic nerve damage with diabetes medicine